Commonwealth Equity Services, LLC Cellectar Biosciences, Inc. Transaction History

Commonwealth Equity Services, LLC

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2021 Jan 31, 2022	BUY	$6.1 - $10.2 $14,182 - $23,715	2,325 Added 6.74%	36,799 $24,000
Q3 2021 Oct 29, 2021	BUY	$8.2 - $12.4 $61,352 - $92,776	7,482 Added 27.72%	34,474 $31,000
Q2 2021 Aug 11, 2021	BUY	$11.8 - $18.2 $47,754 - $73,655	4,047 Added 17.64%	26,992 $32,000
Q1 2021 May 04, 2021	BUY	$15.2 - $25.0 $114,456 - $188,250	7,530 Added 48.85%	22,945 $36,000
Q4 2020 Feb 11, 2021	BUY	$11.2 - $27.7 $172,648 - $426,995	15,415 New	15,415 $32,000

Ticker CLRB
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 6,114,290
Market Cap $13M
Description
Cellectar Biosciences, Inc., a clinical biopharmaceutical company, focuses on the discovery, development, and commercialization of drugs for the treatment of cancer. Its lead phospholipid drug conjugate (PDC) candidate is CLR 131 (iopofosine I-131), which is in Phase 2 clinical study in patients with relapsed or refractory (r/r) Waldenstrom's ma...

Get notified when there are updates to the investment portfolio of Commonwealth Equity Services, LLC, based on Form 13F filings with the SEC.

Stay updated on Commonwealth Equity Services, LLC with notifications on news.